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Background: Patients with familial adenomatous polyposis (FAP) develop duodenal and ampullary
polyps that may progress to malignancy via the adenoma–carcinoma sequence.
Objective: The aim of this study was to review a large series of FAP patients undergoing pancreati-
coduodenectomy for advanced duodenal and ampullary polyposis.
Methods: A retrospective case notes review of all FAP patients undergoing pancreaticoduodenectomy
for advanced duodenal and ampullary adenomatosis was performed.
Results: Between October 1993 and January 2010, 38 FAP patients underwent pancreaticoduodenec-
tomy for advanced duodenal and ampullary polyps. Complications occurred in 29 patients and periop-
erative mortality in two. Postoperative histology revealed five patients to have preoperatively undetected
cancer (R = 0.518, P < 0.001).
Conclusions: Pancreaticoduodenectomy in FAP is associated with significant morbidity, but low mor-
tality. All patients under consideration for operative intervention require careful preoperative counselling
and optimization.
Keywords
familial adenomatous polyposis, adenomatosis, pancreaticduodenectomy
Received 20 July 2010; accepted 8 December 2010
Correspondence
James R. A. Skipworth, Department of Surgical and Interventional Sciences, University College London,
4th Floor, Medical School Building, 74 Huntley Street, London WC1E 6DH, UK. Tel: + 44 20 7403 7866.
Fax: + 44 20 7679 6470. E-mail: j.skipworth@ucl.ac.uk
Introduction
Familial adenomatous polyposis (FAP) is an autosomal dominant,
generalized disorder of tissue growth regulation secondary to
mutations of the adenomatous polyposis coli (APC) gene on
chromosome 5.1,2 The defining phenotypic feature is the develop-
ment of multiple colorectal adenomas in the early adolescent
period, which usually undergo malignant change by the third or
fourth decades of life. However, mortality caused by colorectal
cancer in FAP has significantly decreased following the wide-
spread introduction of prophylactic colectomy, and duodenal
cancer and desmoid disease are now the most significant causes of
death in patients with FAP.3
Familial adenomatous polyposis patients develop multiple
adenomatous polyps in the small as well as the large bowel and
these can similarly become symptomatic or undergo malignant
change.4–7 Small bowel polyps occur almost exclusively within the
duodenum and ampulla, although they also occur on ileostomies
and within ileoanal pouches.8 The cumulative incidence of
duodenal polyps in FAP increases with age to reach 65% at 38
years and 90–95% by 70 years.9,10
Duodenal adenomas can undergo dysplastic change,most often
in the second and third parts of the duodenum,11 where prolonged
contact with bile acids may lead to mutational changes in the
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surrounding mucosa.12–14 However, only approximately 5% of all
duodenal polyps will undergo malignant change,10 via the
adenoma–carcinoma sequence,4–7 and the cumulative incidence of
duodenal cancer in FAP is 4.5% at 57 years.9
The Spigelman scoring system takes into account the polyp
number, size, histology and degree of dysplasia15 (Table 1) and is
applicable to duodenal and periampullary regions.16 Higher scores
indicate greater risk for neoplastic transformation: the risk for
developing duodenal cancer over 10 years is 2% in Spigelman
stages II and III, and 36% in stage IV.17 However, the identification
of patients at risk for developing neoplastic disease remains prob-
lematic because, although the cumulative incidence of Spigelman
stage IV is 52% at the age of 70 years,9 the rate of progression
between stages is highly variable and the disease can take 4–11
years to progress from one stage to another.18
Ampullary adenomatosis has been shown to correlate strongly
with the degree of duodenal polyp burden and is estimated to
occur in approximately 28% of FAP patients.16 Further, the risk for
malignant transformation may be higher in patients with a larger
periampullary than duodenal polyp burden and the cumulative
risk for developing stage IV disease and adenocarcinoma in the
periampullary region by 60 years of age has been estimated as 20%
and 10%, respectively.19
Early identification of malignant duodenal and ampullary inva-
sion may be insufficient to decrease mortality and many centres
therefore offer operative intervention following the diagnosis of
benign but advanced disease (Spigelman stage III or IV).17 St
Mark’s Hospital in London introduced endoscopic surveillance
for duodenal and ampullary polyps in 1988 (Table 2); outcomes of
the practice of utilizing pancreaticoduodenectomy for the man-
agement of advanced duodenal and ampullary adenomatosis are
analysed and presented here.
Materials and methods
Endoscopic surveillance
Since the initiation of a surveillance programme in 1988, all FAP
patients undergoing follow-up at the Polyposis Registry (St
Mark’s Hospital, London) are subject to endoscopic surveillance
for duodenal and ampullary polyps. Surveillance commences at
the age of 25 years (no small bowel polyps requiring treatment at
younger ages have been observed) via a side-viewing duodenos-
cope to optimize views of the ampullary and periampullary
region. Duodenal polyp size is measured by comparison with
open biopsy forceps and the number of polyps defined as the
number of discrete areas of mucosal abnormality. Multiple biop-
sies are taken for assessment of histology and dysplasia, and
completion of Spigelman staging.
Patients are followed according to their Spigelman stage
(Table 2) and referred for consideration of surgery when they are
diagnosed with Spigelman stage IV disease or with suspected or
histologically proven malignancy. Patients with diffuse duodenal
or ampullary adenomatosis (>20 polyps; score of 3 for polyp
number on Spigelman staging) are also considered for surgery at
Spigelman stage III.
Surgical management
All FAP patients in the Polyposis Registry with advanced duodenal
or ampullary adenomatosis are referred to a single centre (Uni-
versity College London Hospital [UCLH]) for consideration of
pancreaticoduodenectomy (unless a patient has a particular pref-
erence for referral elsewhere). All patients undergo preoperative
staging via computed tomography (CT) and endoscopic ultra-
sound (EUS), and further examinations and assessments (includ-
ing cardiopulmonary exercise [CPEX] testing) are arranged as
necessary. All patients undergo pancreaticoduodenectomy with
reconstruction via pancreaticogastrostomy (PG) formed by the
burial of the pancreatic remnant in the posterior wall of the
Table 2 Current follow-up and management protocol of familial
adenomatous polyposis patients with duodenal and ampullary poly-
posis, according to Spigelman stage
Spigelman stage Points Action
0–I 0–4 Repeat endoscopy at 5 years
II 5–6 Repeat endoscopy at 3 years
III 7–8 Repeat endoscopy at 6 months
Consider endoscopic therapy or
chemoprevention
IV 9–12 Repeat endoscopy at 6 months
Computed tomography and
endoscopic ultrasound staging
Consider surgery or endoscopic
therapy + chemoprevention
Cancer N/A Surgery
This protocol was developed by the Polyposis Registry at St Mark's
Hospital, in combination with the Department of Hepatopancreaticobil-
iary Surgery at University College London Hospital
N/A, not applicable
Table 1 Spigelman scoring for duodenal and periampullary polyps in familial adenomatous polyposis15
Polyps, n 1–4 5–20 >20
Polyps, size 1–4 mm 5–10 mm >10 mm
Histology Tubular adenoma Tubulovillous adenoma Villous adenoma
Dysplasia Mild Moderate Severe
Points 1 2 3
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stomach utilizing two layers of 3–0 polydioxanone sutures (PDS)
(Ethicon, Inc., Somerville, NJ, USA), and the insertion of a
common bile duct (CBD) stent.
Postoperative complications
Anastomotic leaks were diagnosed via CT or contrast study and
postoperative haemorrhage via CT angiogram or clinically. Clini-
cal diagnosis was also used to identify both pancreatic exocrine
insufficiency (based on a clinical diagnosis of steatorrhoea, supple-
mented by faecal elastase tests where necessary) and delayed gastric
emptying (based upon symptoms of nausea, vomiting and
decreased oral intake, some of which may be attributable to bile
reflux); however, such gastrointestinal (GI) diagnoses can be diffi-
cult to assess in FAP patients who have undergone prior colectomy.
Patient identification
Familial adenomatous polyposis patients undergoing pancreati-
coduodenectomy for advanced duodenal and ampullary
adenomatosis were retrospectively identified from surgical data-
bases at UCLH, data held at the Polyposis Registry and via contact
with general practitioners and alternative operating centres. Fol-
lowing patient identification, a review of computerized and
written hospital notes, pathology results and operative notes was
undertaken and all data entered into a relational database using
Microsoft Office Access 2007 (Microsoft, Redmond, WA, USA).
Statistical analysis
Differences among proportions of categorical variables (i.e. post-
operative morbidity and mortality) were compared using Fisher’s
exact test. Pearson’s correlation coefficient model was used to
indicate the strength and direction of the relationship between
preoperative endoscopic biopsy histology and surgical resection
histology. Outcome measures of survival and all-cause mortality
rates were analysed using the Kaplan–Meier log-rank test. Two-
tailed P-values of <0.05 were considered to indicate statistical
significance. Statistical analysis was carried out using spssVersion
17.0 (SPSS, Inc., Chicago, IL, USA).
Results
Demographics
Between October 1993 and January 2010, 46 patients were
referred from the Polyposis Registry at St Mark’s Hospital for
consideration of surgical intervention. Of these, 41 patients were
referred to a single centre (UCLH) and five were referred to alter-
nate UK centres and have been excluded from analysis. Of the 41
patients, one underwent polypectomy and cholecystectomy and
two were found to be inoperable at laparotomy; of the latter two
patients, one had widespread, intra-abdominal, malignant disease
and one had extensive intra-abdominal desmoid disease.
Thus, 38 FAP patients underwent pancreaticoduodenectomy
for advanced duodenal and ampullary polyps at a single centre,
representing approximately 5.0% of all patients undergoing
primary colonic surgery for FAP at St Mark’s Hospital. The study
cohort included 17 male and 21 female FAP patients with a
median age of 49 years (range: 32–67 years).
Preoperative staging
Four of the 38 patients were referred with Spigelman stage III
disease; all four underwent pancreaticoduodenectomy for diffuse
polyps involving the duodenal or ampullary regions. Of the
remaining patients, 27 had Spigelman stage IV disease and four
had a preoperative diagnosis of malignancy on endoscopic sur-
veillance (one duodenal, three ampullary). In three patients, the
preoperative Spigelman stage was not given.
Surgical management
All 38 patients were operated upon at a single centre, undergoing
pancreaticoduodenectomy by one of two consultant surgeons.
The number of patients undergoing pancreaticoduodenectomy
increased over time: 14 of the 38 patients underwent resection
during 1993–2001 and 24 underwent resection during 2002–2010
(P = 0.003, one-sample t-test). The median length of stay was 38
days (interquartile range [IQR]: 15–51 days) and the median
follow-up was 42 months (IQR: 13–99 months).
Postoperative histology
Postoperative histology revealed five patients to have preopera-
tively undetected cancer (four duodenal, one ampullary). Two
further patients were also stage-upgraded on surgical histology
(fromSpigelman stage III to IV),whereas four patients were down-
graded (from Spigelman stage IV to III). Therefore, postoperative
histology revealed nine cancers in total, of which five were duode-
nal and four were ampullary. Correlation between preoperative
endoscopic and postoperative surgical staging (Fig. 1) revealed a
Pearson’s kappa correlation coefficient of 0.518 (P < 0.001).
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Figure 1 Analysis of preoperative and operative staging showed five
patients to have preoperatively undetected cancer (four duodenal
and one ampullary; Pearson's kappa correlation coefficient: 0.518
[P < 0.001])
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All-cause and cancer-related five-year survival (Fig. 2) was
lower in patients with postoperative histology illustrating frank
malignancy (n = 9) than in patients with Spigelman stage III or IV
disease (n = 29) (62.5% vs. 81.6% [P = 0.325], 62.5% vs. 88.5%
[P = 0.116], respectively), although these differences did not reach
statistical significance.
Outcome
Two patients died while in hospital, both frommulti-organ failure
after re-operation for intra-abdominal haemorrhage resulting
from a pseudoaneurysm which developed following a diagnosed
anastomotic leak. Another six patients died following discharge,
four from metastatic disease (one at 11 months, one at 13 months
and two at 3 years after surgery), one from a glioblastoma (at 10
months after surgery) and one from unknown reasons (Fig. 3).
Postoperative complications were diagnosed in 29 patients
(Fig. 4). The most common complication was anastomotic leak,
which occurred in 16 patients, who were treated via radiological
drain insertion, although one required laparotomy for biliary peri-
tonitis and three developed enterocutaneous fistulae. Significant
postoperative haemorrhage occurred in seven patients (five with
confirmed anastomotic leaks), necessitating three re-laparotomies
for the cessation of haemorrhage (two patients died) and two
angiographic embolizations of a gastroduodenal artery and a
16
14
12
10
8
6
4
2
0
Postoperative leaks
Enterocutaneous fistulae
Postoperative haem
orrhage
Laparotom
y for biliary peritonitis
Lym
phatic leak
Recurrent cholangitis
Polyp at gastrojejunal anastom
osis
Steatorrhoea
Delayed gastric em
ptying
Acute pancreatitis
Deep vein throm
bosis + pulm
onary em
bolus
Diabetes m
ellitus
Sm
all bowel obstruction
P
at
ie
nt
s,
 n
Figure 4 Postoperative complications in 38 familial adenomatous
polyposis patients undergoing pancreaticoduodenectomy for
advanced duodenal and ampullary adenomatosis
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Figure 2 Longterm follow-up of 38 familial adenomatous polyposis
patients undergoing resection for advanced duodenal and ampullary
adenomatosis illustrates a shorter, overall 5-year survival in patients
with postoperative histology demonstrating frank malignancy com-
pared with those with Spigelman stage III or IV disease (62.5% vs.
81.6%; P = 0.325)
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Figure 3 All-cause mortality in 38 familial adenomatous polyposis
patients undergoing resection for advanced duodenal and ampullary
adenomatosis
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jejunal vessel. Exocrine pancreatic insufficiency occurred in 13
patients and delayed gastric emptying in four.
Patients were subsequently grouped according to their highest-
grade complication on the revised Clavien–Dindo classification20
(Table 3,Fig. 5),which revealed that 19patients had a complication
of grade III or above. However, there was no significant difference
in complication rate between patients with Spigelman stage III/IV
(n = 23) and patients with malignancy (n = 6) (P = 0.830).
Discussion
This report represents the largest published series of pancreati-
coduodenectomies for advanced duodenal and ampullary
adenomatosis in FAP. The results suggest that pancreati-
coduodenectomy for advanced duodenal and ampullary polyps
in FAP is associated with significant perioperative
morbidity. However, a mortality rate of 5% is comparable
to figures derived from series investigating outcomes of
pancreaticoduodenectomy for non-FAP malignant lesions over
the same time period, which demonstrate mortality rates of
3–25%.21–29
The use of pancreaticoduodenectomy in this FAP cohort is
associated with higher morbidity rates than those found in most
pancreaticoduodenectomy series for non-FAP lesions (approxi-
mately 34–57%21,22,29), probably because surgical intervention is
significantly more technically demanding in FAP patients. All the
patients in this study had previously undergone colonic resection
and therefore had significant intra-abdominal adhesions and des-
moplastic change, rendering mobilization technically more diffi-
cult. Further, the non-diseased, normal-texture pancreas, non-
dilated ducts and increased tendency towards postoperative
ileus or small bowel obstruction30 in FAP patients may challenge
anastomotic integrity and contribute to a greater tendency for
anastomotic leak.
Pancreaticogastrostomy reconstruction was originally chosen
over pancreaticojejunostomy (PJ) for the FAP patients in this
series because PG has been associated with a decreased incidence
of postoperative leak, particularly in patients with normal pancre-
atic texture,31–33 which possibly occurs in PJ patients secondary to
jejunal limb oedema, obstruction and distension, which may lead
to anastomotic tension. The close proximity of the stomach and
pancreatic remnant, in combination with the easy placement of
nasogastric tubes for decompression, may decrease anastomotic
tension in PG patients.34 Further, lack of enterokinase in the
gastric remnant in PG patients may prevent pancreatic autodiges-
tion35 and the stomach’s excellent blood supply facilitates the for-
mation of a sound anastomosis.34
Despite this, a significant incidence of anastomotic leak was
discovered in this series and, in addition, some recent randomized
studies and meta-analyses have demonstrated no benefit of one
method of reconstruction over another.36,37 Further, PG formation
has also been associated with pancreatic enzyme inactivation sec-
ondary to the reflux of gastric juices,38–40 which may help to
explain the high incidence of pancreatic insufficiency seen in this
FAP cohort.
The number of patients undergoing pancreaticoduodenectomy
increased over the time course of the series, probably in response
to improvements in the management of colonic disease which
enable more patients to survive to an age at which duodenal
disease becomes significant. These include the generalized
introduction of upper GI surveillance and the identification
of more patients with advanced, benign disease, as well as
Table 3 Clavien–Dindo classification of surgical complications
(adapted from Dindo et al. 200420)
Grade Definition
Grade I Any deviation from the normal postoperative course,
without the need for medication (excluding
anti-emetics, laxatives, analgesics, anti-pyrexials,
diuretics, electrolytes) or intervention (excluding
physiotherapy)
Grade II Pharmacological treatment including blood
transfusion and parenteral nutrition (excluding
medications allowed for Grade I)
Grade III Surgical, endoscopic or radiological intervention
Grade IIIa Intervention not under general anaesthesia
Grade IIIb Intervention under general anaesthesia
Grade IV Life-threatening complication requiring high
dependency unit/intensive therapy unit
management
Grade IVa Single-organ dysfunction
Grade IVb Multi-organ dysfunction
Grade V Patient death
Suffix ‘d’ Complication present at the time of discharge
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Figure 5 Analysis of highest-grade complication per patient, as
defined by Clavien–Dindo grade, in 38 familial adenomatous poly-
posis patients undergoing resection for advanced duodenal and
ampullary adenomatosis
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enhanced disease awareness, which results in increased referrals to
the Polyposis Registry and similar centres.
Endoscopic ultrasound was not available during the first
decade of this series (1993–2003) and thus was not utilized in all
patients. There remains a paucity of published data regarding
the use of EUS in the assessment of upper GI polyps in FAP,
partly because the small numbers of cases make it impossible to
perform a randomized controlled trial for the direct comparison
of CT with CT and EUS. Experiences to date indicate that
duodenoscopy and EUS (performed with one oblique viewing
electronic echoendoscope) are complementary to CT and
provide useful information about polyp size, number and het-
erogeneity, depth of invasion (if present), nodal status and evi-
dence of biliary and pancreatic obstruction, and EUS is now
performed routinely as part of disease staging. In particular, EUS
may be useful for the identification of positive nodal status
and/or early pancreatic/biliary obstruction, thus expediting the
decision to refer for surgery rather than to continue endoscopic
surveillance. However, further data on the utility of EUS in this
context are required.
Despite the high morbidity rates associated with the use of
pancreaticoduodenectomy in this study, it remains the most
definitive treatment for advanced duodenal and ampullary
adenomatosis in FAP. Pharmacological and endoscopic ther-
apies can be helpful in delaying or preventing the need for surgery,
but, once advanced or diffuse adenomatosis is present, surgical
strategies are frequently required. Non-steroidal anti-
inflammatory drugs, in particular, have been shown to be of some
benefit. The use of celecoxib resulted in a significant (14–31%)
reduction in duodenal involved areas,41 although its effect upon
cancer prevention remains unknown. The use of sulindac led to
non-significant duodenal polyp regression in one study42 and had
no effect upon periampullary polyps in another.43 However, treat-
ment with ranitidine44 and calciferol has been shown to have no
effect.45 Endoscopic therapy with argon plasma coagulation and
Nd-YAG laser has been attempted, with varying results.46
Endoscopic mucosal resection may represent a less invasive
method than surgery for managing some stage III and IV patients,
possibly in combination with drug therapies. However, open
polypectomy via duodenotomy for the removal of large polyps
has proved largely unsuccessful because not only does this proce-
dure incorporate the risks of laparotomy and the triggering of
desmoid disease, but any benefit is short-lived as polyps recur
after 6–36 months18,47,48 and progression to further Spigelman
stages occurs after 53 months.47 Similarly, advanced ampullary
lesions can be locally removed by endoscopic49 or open ampullec-
tomy.However, endoscopic ampullectomy carries a risk of incom-
plete resection margins, repeat procedures and complications
(20%).50 To date, surgical ampullectomy has been shown to carry
a low risk of both morbidity and recurrence in patients without
invasive disease51,52 or with invasive lesions measuring <2 cm.53
Pylorus-preserving pancreaticoduodenectomy, although con-
sidered a less aggressive procedure than definitive pancreati-
coduodenectomy, still carries significant complication and
mortality rates (40% and 4.5%, respectively)54 and the inherent
nature of the procedure means that de novo lesions are capable of
arising in residual small bowel.55 Pancreas-sparing duodenectomy
was developed as a similarly less aggressive procedure for the
treatment of duodenal disease because it leaves the entire pancreas
in situ and decreases the number of anastomoses required.
However, it has been shown to have short-termmorbidity (62% vs.
57%; P > 0.05) and mortality (4% vs. 3%; P > 0.05) rates compa-
rable to those of standard pancreaticoduodenectomy for ampul-
lary adenocarcinoma.29 Further,operative techniques that spare the
pancreas leave areas of ampullary mucosa that may still undergo
malignant change56 and may also result in increased anastomotic
tension secondary to delayed gastric emptying, as well as adversely
affecting the function of the patient’s ileoanal pouch.8
Wide disease variability exists among FAP patients and only
36% of patients with stage IV disease will develop cancer.9,57,58
Therefore, given the high postoperative morbidity and mortality
rates, some have previously advocated a watch-and-wait policy in
patients with advanced but benign disease. However, once malig-
nant duodenal or ampullary disease is established, prognosis is
poor.3,59 Further, a discrepancy between endoscopic biopsy and
surgical resection histology has been noted in this study and
others54,60,61 and some patients may therefore have preoperatively
undetected malignancy, further mandating the use of definitive
resection in advanced but benign disease.
For patients in whom complete resection is possible, the long-
term prognosis can be good. However, although distal small
bowel polyps are less likely to develop62 and less likely to
undergo dysplastic and malignant change than duodenal pol-
yps,63 further malignant lesions may still be diagnosed in
residual small bowel if FAP patients are followed for sufficient
periods of time.64
Currently, the selection of FAP patients requiring surgical inter-
vention for high risk of duodenal and ampullary malignant trans-
formation remains challenging; improved methods of identifying
patients at risk are required. Thus, FAP patients with advanced
duodenal and ampullary adenomatosis require careful counsel-
ling and preoperative optimization as surgical intervention still
carries significant rates of morbidity and mortality.
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